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Abstract 
Depression is one of the most prevalent mental illnesses within society today, with overarching 
effects in the social, personal, and professional lives of millions of individuals who are suffering. 
The typical treatment for major depression is often a prescription of an antidepressant, either 
exclusively or combined with another form of treatment, such as psychotherapy. The intended 
effect is to increase levels of neurotransmitters such as serotonin and dopamine within the brain 
to regulate mood and emotion. While this treatment is effective for some patients, not all find 
relief. Exploring and extending research into other substances that effect the 5-
hydroxytryptamine (5-HT) and dopamine systems, such as psychedelics and cannabinoids, may 
reveal new ways to alleviate patient’s depressive symptoms. In a regulated, controlled, and 
supervised setting, the use of substances such as LSD, psilocybin, and marijuana could expand 
the efficacy and impact of depression treatment for patients who have found limited relief or 
developed treatment resistance to traditional antidepressants.   
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Approximately 13% of the general population suffers from Major Depressive Disorder, 
which is characterized by symptoms such as depressed mood, loss of interest in once pleasurable 
activities, change in appetite or sleeping patterns, fatigue, and feelings of worthlessness (Centers 
for Disease Control and Prevention, 2013). These symptoms can often affect individuals’ lives, 
both personal and professional. The prevalence of this mental illness has prompted research into 
the causes and possible treatments. Biologically, depression appears to be associated with 
changes in the 5-hydroxytryptamine (5-HT/serotonin) neurotransmitter system that results in 
lower levels of serotonin, which has effects on mood, emotion, and cognition (Ioannidis, 2008). 
To adjust these abnormal levels of neurotransmitters, several drug classes have been developed 
to target and increase the transmission of serotonin. Such drug classes include select serotonin 
reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic 
antidepressants (TCAs). While such pharmacological treatments have improved symptoms in 
some patients, others have found little relief with such conventional methods, which leads to 
questionable levels of efficacy (Ioannidis, 2008). In the search for more effective treatments, 
some researchers and patients have begun turning their attention to alternative options.  
              The standard method that physicians and psychiatrists use to treat depressive 
symptoms are antidepressants such as MAOIs, tricyclics, and SSRIs. MAOIs are the oldest, often 
referred to as the first-generation antidepressants. Their mechanism of action involves blocking 
the enzyme monoamine oxidase, (MAO), that breaks down monoamines such as serotonin. This 
results in higher levels of monoamines, which is believed to improve mood regulation and 
emotional states.  Tricyclic antidepressants were developed next, and have a mechanism of 
action that works by inhibiting the reuptake of biogenic amines, specifically norepinephrine and 
serotonin. SSRIs specifically target the reuptake of serotonin, which increases the amount within 
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the synapse (Ioannidis, 2008). Prescribing these drugs is often the first and most typical 
treatment modality prescribed by healthcare providers. Yet fewer than 50% of patients fully 
remit after antidepressant treatment (Trivedi, Nieuwsma, Williams, & Baker, 2009). In some 
cases, patients are prescribed different antidepressants, experience a change in dose, or add 
additional treatment such as psychotherapy. Still some patients remain treatment-resistant and 
struggle to deal with their symptoms or side effects experienced while on some antidepressant 
medications, such as headaches or nausea. Some side effects are more serious, such as suicidal 
thoughts or hallucinations, which can prove to be more harmful than the depression itself 
(Trivedi, Nieuwsma, Williams, & Baker, 2009). The struggle to isolate effective treatments for 
depression has led many researchers to look beyond conventional pharmacotherapy and into 
more experimental treatments, such as the use of psychedelics or cannabinoids, to help those 
who continue to suffer.  
            A psychedelic refers to a drug that can produce hallucinations and apparent expansion of 
consciousness. Some of the most well-known psychedelics are lysergic acid diethylamide (LSD) 
and psilocybin, which are currently categorized by the Drug Enforcement Administration (DEA), 
as a Schedule I drugs and are illegal for any purpose (Passie, Halpern, Stichtenoth, Emrich & 
Hintze, 2008). LSD is a semisynthetic derivative of an alkaloid found in ergot fungus, known as 
lysergic acid moiety. Psilocybin is a compound found naturally in mushrooms in the genus 
Psilocybe. Throughout the 1950s, psychedelics were used in experiments to induce “model 
psychosis” and to enhance psychotherapeutic treatments on a range of patients, including 
alcoholics and those suffering from personality disorders. Clinical trials continued by large 
pharmaceutical companies such as Sandoz, until the mid-1960s (Passie, Halpern, Stichtenoth, 
Emrich & Hintze, 2008). By that time, government protests had begun as psychedelics like LSD 
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were gaining popularity as recreational drugs. Research funds became limited as government 
protests began and experimentation dramatically dropped by the late 1970s.  
          Pharmacologically, psychedelics have various effects. They work primarily on the brain’s 
5-HT system and alter the transmission of serotonin in different regions. The primary receptor 
that psychedelic substances act upon is the 5-HT2A autoreceptor (Griffiths et al., 2016). 
Substances such as LSD and psilocybin act as agonists at the 5 HT2A receptor, which has strongly 
been correlated with hallucinogenic effects, altering perception, cognition, and emotion (Passie, 
Halpern, Stichtenoth, Emrich & Hintze, 2008). When binding to the 5-HT2A receptor, 
psychedelics are inhibiting the inhibitory receptor, resulting in an overall increase of serotonin. 
Psilocybin administration has also been shown to decrease activity within the amygdala, which 
has a strong correlation with emotional responses (Kraehenmann et al 2015). While the exact 
neural mechanisms of this effect are not well-known, the ability to induce positive mood changes 
supports the potential of psilocybin and other psychedelics in their ability to work as 
antidepressants in more widespread ways than traditional antidepressants.  
          With such effects on serotonin levels, psychedelics have been a targeted antidepressant in 
many animal studies. A study conducted in 2014 used LSD to combat depressive-like behavior 
in rats (Buchborn, Schroder, Hollt, & Grecksch, 2014). The researchers performed at bilateral 
dissection of the rat’s olfactory bulbs, which resulted in behavioral disturbances such as stress-
associated locomotor agitation and avoidance learning. In human subjects, these symptoms can 
be associated with the agitation and emotional biases observed in some clinically depressed 
patients (Buchborn, Schroder, Hollt, & Grecksch, 2014). Following the bulbectomny, LSD was 
subcutaneously administered once every 24 hours for 11 days at a dosage of 0.13mg/kg. The 
same procedure was conducted with sham rats as a control, and with another group of rats who 
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had the bulbectomy, but were injected with saline. During this time, the rats were assessed by a 
pole-jumping test, where they had to learn to avoid electrical stimulation of their feet by jumping 
onto a pole. Each day their time was recorded. Initially, the bulbectomized rats performed at 
levels similar to the saline injected rats, while the sham rats performed the best. However, the 
bulbectomized rats receiving LSD began to improve over the course of a couple of days, and by 
the end of the 11 days, their responses had normalized to the level of the sham rats, while 
significantly differing from the saline rats (Buchborn, Schroder, Hollt, & Grecksch, 2014). 
Overall, the researchers were able to conclude that the LSD treatment was able to decrease 
avoidance learning, which has been proposed to model decreases in emotional stress.  
            Another psychedelic substance, psilocybin, also shows promise in being used as an 
antidepressant. A recent study was conducted specifically on cancer patients who show 
symptoms of depression and/or anxiety (Griffiths et al., 2016). This double-blind study assigned 
patients into one of two groups who received two doses of psilocybin. One group received a high 
dose (22 or 30mg/70kg) at their first session and a low dose at their second session (1 or 
3mg/70kg) five weeks later. Prior to the psilocybin administration sessions, baseline 
measurements of depression and anxiety were taken by clinicians using the Hamilton Depression 
Rating Scale (GRID-HAMD) and the Hamilton Anxiety Rating Scale (HAM-A). Patients were 
also assessed at a six-month follow-up session. Results of the assessments showed that after the 
first session of psilocybin administration, 92% of high-dose participants showed a decrease in 
depressive symptoms. Low dose patients showed a 32% decrease in symptoms. Patients were 
also able to report their subjective ratings of anxiety, depression, and mood disturbance, all of 
which decreased after psilocybin administration. Clinician and self-reports of quality of life, 
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meaning, death acceptance, and optimism increased and were sustained at six months for 78% of 
patients experiencing depressive symptoms (Griffiths et al., 2016). 
           Another study targeted antidepressant resistant depressive patients who had failed to see a 
relief in symptoms after at least two courses of antidepressants (Carhart-Harris et al. 2016). Each 
patient was diagnosed with moderate-severe major depression. Psilocybin was administered 
orally in two sessions, the first dosage containing 10mg and the second containing 25mg, with a 
7-day gap between sessions. Measurements of depressive symptoms were measured using the 
HAM-D and the Beck Depression Inventory (BDI) before administrative testing, 7 days after 
treatment, and three months afterward. All patients showed a decrease in depressive symptoms 
after 1 week, and 58% achieved remission after three months (Carhart-Harris et al. 2016).  
          Another path for future nontraditional antidepressant treatment is the use of cannabinoids. 
One of the major components of these substances is tetrahydrocannabinol, (THC), the active 
ingredient in Cannabis, which is more commonly known as marijuana. Drugs that contain THC, 
like marijuana, have been shown to affect several neurotransmitter systems in the brain, 
including the 5-HT and dopamine, (DA) systems. These systems, being linked to mood 
regulation and feelings of pleasure and reward, are often targeted for antidepressant treatment. 
The human body contains its own endocannabinoid system that is involved in emotional, 
cognitive, and motivational processes. Within the central nervous system, the presynaptic 
cannabinoid type 1, (CB1), receptors, are found in areas such as the cerebellum, basal ganglia, 
hypothalamus, hippocampus, medulla, and areas of the cerebral cortex (Valdez, 2017). The 
widespread locations and functional areas of these receptors that are activated by endogenous 
and synthetic cannabinoids allow for many complex effects to take place that alter behavior and 
neurochemistry. By better understanding these receptor pathways and the effects that certain 
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drugs can have on them, research may gain insight into developing more directed and efficient 
ways of to altering the activity of these receptors to benefit those suffering from psychological 
disorders.  
             In one rodent based study, the focused cannabinoid used was cannabidiol, (CBD), which 
lacks the psychoactive ingredient of THC (Breuer et al, 2016). In this study, mice were injected 
with fluorinated CBD solutions and then subjected to a number of behavioral tests, most notably 
the forced swim test (FST). Those mice who received the CBD injections, specifically in a 
concentration of 3mg/kg, spent less time immobile in the forced swim test when compared to 
control mice. Immobility has been proposed to model a depressive-like state. These findings are 
promising for the more widespread use of CBD, as it can already be purchased in variety of 
forms in stores today, including oils and gummies. Higher doses of medical grade CBD has also 
been to prevent seizures in epileptics, which has shown promise in a growing number of people 
(Project CBD, 2018).  
            The CB1 receptor has been shown to be an important receptor in the potential regulation 
of certain depression symptoms. A lack of CB1 signaling has been shown to produce symptoms 
that mimic major depression (Gorzalka and Hill, 2011). In contrast, the activation of CB1 
signaling has been shown to mimic the behavioral and emotional effects of many common 
antidepressants. In one study, researchers investigated these relationships further in mice by 
inducing depression-like symptoms with corticosterone, (CORT), and then using a combination 
of curcumin, (CUR), and dexanabinol, (HU-211), a synthetic cannabinoid, to counteract the 
depressive effects (He et al, 2017). CUR and dexanabinol both have been shown to have anti-
inflammatory, antioxidant, and neuroprotective effects. Specifically, this study tested the ability 
of a Cur/HU-211 mixture to protect CB1 receptors from the effects of CORT. After analyzing 
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pre-condition levels of both DA and 5-HT, the mice were split into three groups, one which 
would receive injections of the Cur/HU-211 and CORT, one group that would receive only 
CORT, and one which would remain as a control with no injection. Behavioral changes were 
observed in the mice using the FST and brain neurotransmitter tests specifically analyzing DA 
and 5-HT levels. Levels of CB1 mRNA and proteins were also collected to gauge the health of 
the CB1 receptors. The findings were encouraging. The mice that were treated with the Cur/HU-
211 decreased immobility time when compared than the mice only treated with CORT, who 
continued to express depression-like behaviors. In the measurement of neurotransmitter levels, 
the Cur/HU-211 induced more DA and 5-HT specifically in the hippocampus and striatum, 
surpassing the levels of the CORT and control groups. CB1mRNA expression levels were also 
analyzed, and it was found that these levels were highest again in the hippocampus and striatum 
of the Cur/HU-211 group and decreased in the CORT group (He et al, 2017). Collectively, it 
appeared that in a corticosterone induced depression model, a combination of curcumin and 
dexanabinol, a synthetic cannabinoid, was able to reduce depressive-like behavior and alter the 
neurochemicals of mice in a way that could be a future target for human research. 
            Another study analyzed depressive-like behavior and the cannabinoid system by using a 
social isolation stress model (SIS), which has been shown to induce depressive-like behaviors in 
rodents (Haj-Mirzaian et al 2017). The researchers used this model to observe the effects of 
depressive-like behavior in response to certain cannabinoid agonists and antagonists. One 
chemical compound, WIN55, 212-2 was used as a nonspecific cannabinoid agonist, and AM-251 
was used as CB1 antagonist. Both were administered as injections, and each mouse was used 
once in each test condition. To establish pre-injection conditions, a group of mice were held in 
the social condition (SC) in a tank with six other mice, and another group were held in the 
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isolation condition (IC), with minimal experimenter interaction. The mice were then separated 
into a group of saline injections, a group of WIN55-212,2 injections, and a group of AM-251 
injections. After administration, behavioral observation began. A FST and splash test, which 
involved an initial splash of a sucrose solution and sequential observation of grooming behavior, 
were conducted and used as measurements of depressive, motivational, and self-care behaviors. 
The results showed that the mice in the IC significantly increased immobility in the FST and 
decreased grooming behavior in the splash test, supporting its use a depression inducing model. 
The use of WIN55, 212-2 at 3 and 5mg/kg decreased immobility time in the FST and increased 
grooming time in the splash test of IC mice. These effects were not observed in the SC mice. The 
mice who were administered the AM-251 increased immobility time and decreased grooming 
time in comparison to IC mice injected with saline. To add another level of analysis, researchers 
administered a number of injections in a sequential manner, with first an injection of WIN55, 
212-2 one hour before the behavioral tests, and then an injection of AM-251 30 minutes before 
the tests. The results of this condition showed that AM-251 reversed the effects of WIN55, 212-
2, with the same trends of increased immobility and decreased grooming time that were observed 
when only AM-251 was administered in IC mice. Overall, the results suggested that the 
administration of the cannabinoid agonist, WIN55, 212-2, reversed the depressive behaviors 
induced by IC while the administration of CB1 antagonist, AM-251 resulted in depressive-like 
behaviors and reversed the effects of WIN55, 212-2 (Haj-Mirzaian et al 2017). These 
relationships between agonists and antagonists observed in a social isolation model in mice 
provides insight into how such neurochemical relationships may be affected by possible drug 
therapies to combat depression symptoms in humans who may also find themselves in more 
socially isolated conditions. 
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           Although there is a growing base of evidence for the benefits of psychedelics and 
cannabinoids as treatments for depression, approval and accepted medical use will be difficult to 
achieve. Certainly, additional research is needed concerning psychedelic and cannabinoid use in 
relation to depressive symptoms. Research with animal models have produced promising results, 
particularly within rodents, but human studies are rarer. However, there is gaining popularity in 
exploring the possible use of these substances, particularly cannabinoids, as treatments for 
multiple health problems, including pain management and anti-nausea medications for those 
undergoing cancer treatment (Williamson and Evans, 2000). Although not directly studying the 
antidepressant effects of cannabinoids, these studies may offer additional insights into the 
physiology and possible behavioral responses observed when these drugs are utilized, which may 
act as a springboard for future research and acceptance in other areas. Furthermore, while 
medically promising, the past use of psychedelics and cannabinoids as recreational drugs often 
hold them back from being considered as serious medical options (Patra, 2016). Even after 
presenting the public with evidence of the beneficial use, the stigma of these substances as 
“street drugs” that are further associated with other risky behaviors, continues to prevail. 
However, it is important to differentiate medical from recreational use, and that the push to 
legalize substances such as LSD, psilocybin and synthetic cannabinoids would be for intended 
medical use in a public setting, and if necessary, supervised by healthcare professionals 
(Baumeister, Barnes, Giaroli & Tracy, 2014).  In some cases, a slow integration of medical 
marijuana treatment is beginning to grow, and it is possible that future facilities offering 
psychedelic use might establish themselves in a similar way. These developments would likely 
be established by individual states, and even then, be limited in the population eligible for 
treatment. 
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          According to the Centers for Disease Control and Prevention, depression is the most 
common type of mental illness in the United States, and antidepressant medications are among 
the most widely prescribed medications, with billions of dollars in sales each year (Ioannidis, 
2008). Yet the effectiveness of common antidepressants reveals that while some individuals 
experience improvement in their condition, many remain unchanged or minimally influenced by 
typical pharmacological treatments. As mental health continues to become a growing health 
concern, research into other options for treatment should be assessed for potential benefits that 
may affect a wider population in a more comprehensive and effective way. Psychedelics and 
cannabinoids may prove to be the next generation of antidepressant treatment if public and social 
policy agree that the medical potential that these substances may offer in a controlled setting 
outweigh their past use as recreational drugs. A continuation of the research into the mechanisms 
that affect depression and the possible new horizons and clinical trials of treatment options such 
as psychedelics and cannabinoids on their own and in accordance with other therapies may bring 
society closer to combatting the extensive symptoms of depression that affect millions of people 
worldwide.  
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